JPH04506866A - 二抗体ｅｉａ検定法におけるヒト抗ネズミ抗体および異好性抗体の干渉の除去 - Google Patents

二抗体ｅｉａ検定法におけるヒト抗ネズミ抗体および異好性抗体の干渉の除去

Info

Publication number
JPH04506866A
JPH04506866A JP2510079A JP51007990A JPH04506866A JP H04506866 A JPH04506866 A JP H04506866A JP 2510079 A JP2510079 A JP 2510079A JP 51007990 A JP51007990 A JP 51007990A JP H04506866 A JPH04506866 A JP H04506866A
Authority
JP
Japan
Prior art keywords
cea
antibody
eia
assay
samples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2510079A
Other languages
English (en)
Japanese (ja)
Inventor
ビーティ，ジョン・デーヴィッド
ビーティ，バーバラ・ジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JPH04506866A publication Critical patent/JPH04506866A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2510079A 1990-04-25 1990-04-25 二抗体ｅｉａ検定法におけるヒト抗ネズミ抗体および異好性抗体の干渉の除去 Pending JPH04506866A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1990/002239 WO1991016627A1 (en) 1990-04-25 1990-04-25 Removal of human anti-murine and heterophilic antibody interference in double antibody eia assays

Publications (1)

Publication Number Publication Date
JPH04506866A true JPH04506866A (ja) 1992-11-26

Family

ID=22220815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2510079A Pending JPH04506866A (ja) 1990-04-25 1990-04-25 二抗体ｅｉａ検定法におけるヒト抗ネズミ抗体および異好性抗体の干渉の除去

Country Status (4)

Country Link
EP (1) EP0479901A1 (enExample)
JP (1) JPH04506866A (enExample)
AU (1) AU645981B2 (enExample)
WO (1) WO1991016627A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008249738A (ja) * 2008-07-18 2008-10-16 Eiken Chem Co Ltd 免疫反応干渉物質の除去方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
DE69217957T2 (de) * 1991-07-26 1997-08-07 Dade Chemistry Systems Inc Verfahren zur beseitigung von falschen ergebnissen in einem immunoassay
DE19828466A1 (de) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US20040018556A1 (en) * 2002-07-29 2004-01-29 Cantor Thomas L. Reagent and method for determination of a substance using an immunoaggregator
US8592219B2 (en) 2005-01-17 2013-11-26 Gyros Patent Ab Protecting agent
WO2006075964A1 (en) * 2005-01-17 2006-07-20 Gyros Patent Ab A method for co-transporting a reactant with an amphiphilic macromolecular substans in a microfluid transport conduit
EP1957532A4 (en) * 2005-11-21 2009-11-11 Univ Oregon Health & Science METHOD AND REAGENT FOR ELIMINATING OR REDUCING WRONG POSITIVE RESULTS IN THE ANALYSIS OF A SAMPLE
CN101963618B (zh) * 2010-08-31 2014-03-12 上海铭源数康生物芯片有限公司 在抗体微阵列系统中识别异嗜性抗体干扰的方法及应用其检测目标抗原的抗体微阵列芯片
JP7060510B2 (ja) * 2016-09-06 2022-04-26 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬
CN113663646A (zh) * 2021-07-19 2021-11-19 中国计量大学 一种宽谱特异性抗体修饰的磁性金属有机骨架材料的制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4900684A (en) * 1987-06-01 1990-02-13 Immunomedics, Inc. CEA immunoassay free of human anti-mouse antibody false positives
CA2093494A1 (en) * 1992-04-17 1993-10-18 Keisuke Iwata Method for the elimination of non-specific reactions in immuno-assays

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008249738A (ja) * 2008-07-18 2008-10-16 Eiken Chem Co Ltd 免疫反応干渉物質の除去方法

Also Published As

Publication number Publication date
WO1991016627A1 (en) 1991-10-31
AU645981B2 (en) 1994-02-03
AU5965290A (en) 1991-11-11
EP0479901A1 (en) 1992-04-15
EP0479901A4 (enExample) 1994-03-30

Similar Documents

Publication Publication Date Title
Purves et al. Serum alpha‐feto‐protein and primary cancer of the liver in man
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
Schroff et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy
Ott et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites
JP6058585B2 (ja) 甲状腺障害リスクの同定方法
Klein et al. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease: a retrospective analysis of 76 patients over 6–18 years
KR20120057562A (ko) 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도
AU645981B2 (en) Removal of human anti-murine and heterophilic antibody interference in double antibody EIA assays
US20080008710A1 (en) Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma
JPS62259064A (ja) ヒト乳ガンの分析
Hatanaka et al. Factors affecting an increase in spleen volume and association of spleen volume variation with the clinical outcomes of atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a retrospective analysis
Ravaioli et al. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
Price et al. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay
Mazzaschi et al. Nivolumab-induced Guillain-Barré syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma
US20200264178A1 (en) Method and means for diagnosing autoimmune hepatitis using autoantibody markers
WOLLHEIM Immunoglobulin changes in the course of infectious mononucleosis
James et al. Waldenström's macroglobulinaemia in a bird breeder: a case history with pulmonary involvement and antibody activity of the monoclonal IgM to canary's droppings.
JPS63502928A (ja) 自己免疫病の診断法及び診断試薬、自己免疫病の治療剤並びにこれに好適な抗パラタイプ抗体
JP2818658B2 (ja) ヒト動脈硬化症認識モノクロナル抗体およびその製造法
Ebeid et al. Production and Characterization of Immunoradiometric Technique for Measuring of Thyroglobulin in Human Serum.
Einhorn et al. Antibodies to A HeLa Cell Line in Carcinoma of the Cervix Uteri: The effect of radiation therapy
KR102168417B1 (ko) 디프테리아 독소에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
JP4054380B2 (ja) 消化器疾患用診断薬
Affat et al. P0525Evaluation of Point-of-Care Anti-TNF Assays Versus Standard of Care (ELISA) in Reactive Therapeutic Drug Monitoring in Adult IBD Patients: A prospective pilot study
JP2005533243A (ja) ガン疾患の予防、阻害、及び治療のための方法及び薬剤